Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Financials are out.
View:
Post by MrMugsy on Nov 15, 2021 9:54pm

Financials are out.

If I'm reading the information correctly ... "The Company is in active discussions with a potential purchaser of Citagenix."

Not sure if that's a continuation of past negotiations or if it's a new negotiation.
Comment by Doccole on Nov 16, 2021 7:33am
This negotiation has been going on for close to 3 years now, lol deck should be updated soon.  I imagine before radius. the big thing, where we will have out most pop is trials. They need to get into trials,  and we need to have positive  results, and we need someone to write the results as if it's a good thing vs insane gibberish.  
Comment by MrMugsy on Nov 16, 2021 2:37pm
Doccole - don't think it was insane gibberish as I believe it was presented the way FDA wanted it. Problem for investors is ... wasn't they way we expected it. Which leads us to the bigger problem - we didn't have a lowest dose determined which left it open-ended and that was the real confusion. But ... luckily ... we didn't have a lowest expected dose that took us to P3 only to ...more